Advertisement

Drugs & Therapy Perspectives

, Volume 35, Issue 9, pp 460–460 | Cite as

Correction to: Ivosidenib in relapsed or refractory acute myeloid leukemia: a profile of its use in the USA

  • Emma H. McCafferty
  • Katherine Ann Lyseng-WilliamsonEmail author
Open Access
Correction
  • 168 Downloads

Correction to: Drugs & Therapy Perspectives (2019) 35:160–166  https://doi.org/10.1007/s40267-019-00610-2

The original article was originally published Online First without open access. After publication in volume 35, issue 4, pages 160–166, Agios Pharmaceuticals requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Agios Pharmaceuticals. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The original article has been corrected.

Copyright information

© Springer Nature 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations